Effective Strategies for Targeting Oncogenic Stress in Cancer

Oncogenic Stress: Key Mechanisms and Implications for Cancer Therapy

Oncogenic stress refers to the cellular responses triggered by the abnormal activation of oncogenes, such as mutations in the KRAS gene. This activation leads to profound disruptions in cellular homeostasis, resulting in an array of stress responses aimed at enabling cells to cope with the challenges of tumorigenesis. Understanding these mechanisms is vital for developing targeted therapies that can disrupt the survival strategies employed by cancer cells.

Key components of oncogenic stress responses include heat shock proteins (HSPs), the ubiquitin-proteasome system (UPS), autophagy, the nuclear factor erythroid 2-related factor 2-antioxidant response element (NRF2-ARE) signaling pathway, DNA damage response proteins, p53, and redox-regulating proteins. Each of these components plays a specific role in cellular adaptation to oncogenic stress, contributing to tumor progression and therapy resistance.

For instance, KRAS mutations are prevalent in many human cancers, including pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma, and colorectal cancer. These mutations can lead to enhanced cellular proliferation and survival, making KRAS-driven oncogenic stress a prime target for therapeutic intervention. By targeting the stress response pathways activated by KRAS mutations, researchers can identify novel therapeutic opportunities that may enhance the effectiveness of existing treatments or pave the way for innovative therapies.

The Role of KRAS Mutations in Cancer Progression and Treatment

KRAS is a member of the RAS family of small GTPases involved in various signal transduction pathways that regulate cell growth and differentiation. Mutations in KRAS, most commonly occurring at codons 12, 13, and 61, lock the protein in its active GTP-bound state, leading to constitutive activation of downstream signaling pathways that promote uncontrolled cell proliferation and inhibit apoptosis.

The aberrant activation of the KRAS signaling pathway is a hallmark of several aggressive cancers. For example, KRAS mutations account for approximately 90% of PDAC cases and 30% of lung cancers. Tumors harboring KRAS mutations typically exhibit aggressive growth patterns and are often resistant to conventional therapies, including targeted therapies and chemotherapy.

Targeting KRAS directly has proven challenging due to its high affinity for GTP and lack of suitable binding pockets for small molecules. However, advances in drug development have led to the emergence of KRAS inhibitors, such as Sotorasib and Adagrasib, which selectively target specific KRAS mutations. These inhibitors have shown promise in clinical trials, leading to improved outcomes in patients with KRAS-driven tumors. Furthermore, combination therapies that target multiple pathways downstream of KRAS, such as the MAPK and PI3K/AKT pathways, are also being explored to enhance therapeutic efficacy.

Heat Shock Proteins: Dual Functions in Cancer and Therapeutic Targeting

Heat shock proteins (HSPs) are a group of highly conserved proteins that function as molecular chaperones, assisting in the proper folding and stabilization of proteins under stress conditions. In the context of oncogenic stress, HSPs play a dual role. On one hand, they protect cancer cells from stress-induced damage, allowing for survival and proliferation. On the other hand, they can also facilitate apoptosis in response to severe cellular stress.

HSP70 and HSP90 are the most studied members of this family in cancer biology. HSP70 is frequently overexpressed in cancer cells, promoting tumor cell survival by inhibiting apoptosis. In contrast, HSP90 stabilizes several oncoproteins, including mutant p53 and HER2, which are critical for cancer progression. Therefore, targeting HSPs has emerged as a promising therapeutic strategy.

Inhibitors of HSP90, such as 17-AAG (tanespimycin), have shown potential in preclinical and clinical trials by depleting oncoproteins and enhancing the efficacy of chemotherapy. Additionally, HSP70 inhibitors are being investigated to enhance the cytotoxic effects of various anticancer therapies. Understanding the roles of HSPs in oncogenic stress responses may lead to the development of novel strategies aimed at exploiting these pathways for therapeutic benefit.

Autophagy and Its Impact on Tumor Survival and Drug Resistance

Autophagy is a cellular process that degrades and recycles damaged organelles and proteins, playing a crucial role in maintaining cellular homeostasis. In cancer, autophagy can have both tumor-suppressive and tumor-promoting effects depending on the context. During oncogenic stress, autophagy is often upregulated as a survival mechanism, allowing cancer cells to cope with metabolic stress and maintain homeostasis.

Inhibition of autophagy has been shown to sensitize cancer cells to chemotherapy and radiotherapy, suggesting that targeting autophagy may enhance treatment efficacy. Conversely, in established tumors, excessive autophagy can contribute to drug resistance by promoting cell survival under therapeutic stress.

Recent studies have highlighted the role of autophagy in the modulation of various oncogenic pathways. For instance, autophagy can regulate the levels of critical proteins involved in cell survival and apoptosis, such as p53 and BCL-2. Inhibiting autophagy in KRAS-driven cancers has shown promise in preclinical models by enhancing the effects of standard treatments.

Redox Regulation: Targeting Antioxidant Pathways in Cancer Treatment

Redox regulation involves the maintenance of the balance between reactive oxygen species (ROS) and antioxidants within cells. In the context of oncogenic stress, cancer cells often experience increased oxidative stress due to elevated ROS levels, which can lead to DNA damage and promote tumor progression. To counteract this, cancer cells upregulate antioxidant defenses, including the NRF2-ARE pathway.

NRF2 is a key transcription factor that regulates the expression of antioxidant genes in response to oxidative stress. In many cancers, NRF2 is constitutively activated, providing a survival advantage by enhancing the antioxidant response. This can lead to therapy resistance, as cancer cells become less susceptible to treatments that induce oxidative stress.

Targeting the NRF2 pathway presents a therapeutic opportunity to sensitize cancer cells to oxidative stress-induced cell death. Inhibitors that block NRF2 activity or disrupt its interaction with its upstream regulators are currently being explored. Additionally, combining chemotherapy with agents that induce oxidative stress may enhance treatment efficacy in NRF2-dependent tumors.

Targeting the Ubiquitin-Proteasome System in Oncogenic Stress Responses

The ubiquitin-proteasome system (UPS) is a critical cellular mechanism for regulating protein degradation and maintaining protein homeostasis. In cancer, the UPS is often hijacked to promote tumor survival by degrading pro-apoptotic proteins and stabilizing oncoproteins. Therefore, targeting the UPS presents a novel approach to disrupt oncogenic stress responses.

Proteasome inhibitors, such as bortezomib, have shown efficacy in hematologic malignancies by inducing apoptosis in cancer cells through the accumulation of pro-apoptotic factors. Research is ongoing to explore the use of proteasome inhibitors in solid tumors and in combination with other therapeutic agents.

The development of selective inhibitors targeting specific components of the UPS, such as E3 ubiquitin ligases, is also being investigated. These inhibitors could potentially disrupt the survival mechanisms of cancer cells while minimizing effects on normal cells.

Conclusion

Targeting oncogenic stress pathways represents a promising strategy in cancer therapy. By understanding the intricate molecular mechanisms associated with oncogenic stress, researchers can identify novel therapeutic targets to enhance treatment efficacy and overcome resistance. Strategies targeting HSPs, autophagy, redox regulation, and the ubiquitin-proteasome system can provide new avenues for developing effective cancer treatments tailored to individual tumor characteristics.

References

1. Iovanna, J., Estaras, M., Grasso, D., Fernández Zapico, M. E., Neira, J. L., & Santofimia-Castaño, P. (2025). Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review. Medicine, 104(24), e42857. https://pubmed.ncbi.nlm.nih.gov/12173300/

2. Soppe, S. E., Hinton, S. P., Halula, J. C., Lund, J. L., Baggett, C. D., Pruitt, S. L., Mullins, M. A., Dillon, E. C., Barclay, M. E., Thompson, M., & Lyratzopoulos, G. (2024). Registry versus claims-based index dates for studies of cancer diagnosis in administrative data. Cancer Causes Control, 35(1), 1-12. https://doi.org/10.1007/s10552-024-01953-6

3. Li, C.-L., Zhuang, J.-K., Liu, Z., Huang, Z.-R., Xiang, C., Chen, Q.-Y., Chen, Z.-X., & Shi, Z.-S. (2025). MicroRNA-29a-5p attenuates hemorrhagic transformation and improves outcomes after mechanical reperfusion for acute ischemic stroke. Noncoding RNA Research, 10(1), 1-15. https://doi.org/10.1016/j.ncrna.2025.05.016

4. Muacevic, A., Adler, J. R., Li, Y., Ong, S. J., Anil, G., Mithiran, H., Rajendran, P. C., Yap, C. W., & Tam, J. K. (2025). Computed tomography guided coil localization and uniportal video-assisted thoracic surgery resection of small lung lesions. Cureus, 15(3), 1-10. https://doi.org/10.7759/cureus.84355

5. Schmid, B. C., & Decker, S. (2025). Multifaced anticancer potential of doxorubicin: Spotlight on breast cancer. Medicine (Baltimore), 104(24), e42857